Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CA-170 |
Synonyms | |
Therapy Description |
CA-170 is a small molecule inhibitor of PD-L1 (CD274) and VISTA (VSIR), which may stimulate T-cell mediated immune response against tumor cells (Ann Oncol. 2017 Sep 18; 28 (Suppl_5): Abstract 1141PD, PMID: 32554470). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CA-170 | AUPM 170 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | CA-170 is a small molecule inhibitor of PD-L1 (CD274) and VISTA (VSIR), which may stimulate T-cell mediated immune response against tumor cells (Ann Oncol. 2017 Sep 18; 28 (Suppl_5): Abstract 1141PD, PMID: 32554470). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02812875 | Phase I | CA-170 | A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas | Completed | USA | GBR | ESP | 1 |